Stock Track | Celcuity Soars 5.04% Intraday on FDA Priority Review and Expanded Phase 3 Trial for Breast Cancer Drug

Stock Track05-14

Celcuity Inc's stock soared 5.04% during intraday trading on Thursday, driven by multiple positive regulatory and clinical developments for its lead drug candidate, gedatolisib.

The surge follows news that the U.S. Food and Drug Administration has granted Priority Review to Celcuity's New Drug Application for gedatolisib, setting a Prescription Drug User Fee Act target date of July 17, 2026. Additionally, the company announced the expansion of its Phase 3 VIKTORIA-2 trial to include a separate cohort of endocrine-sensitive patients with HR+/HER2- advanced breast cancer, broadening the potential patient population for the treatment.

These developments come after positive prior study data and discussions with the FDA, which also included a Type B meeting on the amended Phase 3 trial design. Celcuity has further strengthened its intellectual property portfolio by submitting a patent application for a subcutaneous formulation of gedatolisib.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment